MDS Nordion Offers Advanced Cancer Therapy Systems in Europe

Ottawa, Canada (ots/PRNewswire) - The MDS Nordion Equinox, a
state-of-the-art cancer therapy system, and Avanza, a patient
positioning treatment table, have received CE Mark approval and are
now commercially available in Europe.

The Equinox is a unique external beam therapy system providing
cancer care professionals with modern functionality to maximize
productivity and increase flexibility ensuring patients receive
advanced, timely care. The Avanza patient positioning treatment table
offers health care providers with stability and accuracy and supports
all modern treatment techniques, including specialized treatments
that require precision and reproducibility.

"The need to improve timely access to cancer treatment is
increasingly a concern in Europe and across the global cancer-care
community," says Jim Warrington, Head of Radiotherapy Physics, at the
Royal Marsden, Sutton, England. "Cancer care professionals need
efficient and effective cancer tools like MDS Nordion's Equinox and
Avanza to manage workload and provide patients with quality care when
they need it."

According to the World Health Organization, across the globe,
rates of cancer are on the rise. In 2004, Europe diagnosed nearly 2.9
million new cancer cases and had more than 1.7 million cancer deaths
demonstrating the increased need for sophisticated, accessible and
efficient treatment options.

"Today's oncology clinics need practical solutions to meet
clinical challenges as the demand for treatment services increases
world-wide," said Steve West, President of MDS Nordion. "We are proud
to be offering the European medical community and its patients our
advanced cancer therapy system that delivers predictable outcomes
with timely and effective treatment."

The Equinox represents MDS Nordion's continued commitment to
deliver reliable, efficient and effective patient care solutions.
Recognized as a leader in quality and regulatory excellence, some
1,200 MDS Nordion cancer therapy systems deliver 45,000 cancer
treatments in over 80 countries every day.

About MDS Nordion

MDS Nordion (www.mds.nordion.com) is a world leader in
radioisotopes, radiation and related technologies. MDS Nordion is
part of MDS Inc. (TSX:MDS; NYSE:MDZ). MDS Inc. has more than 8,800
highly skilled people in 28 countries. We provide a diverse range of
superior products and services to increase our customers' speed,
precision and productivity in the drug development and disease
diagnosis processes. We are a global, values-driven health and life
sciences company, recognized for our reliability and collaborative
relationships as we help create better outcomes in the treatment of
disease. Find out more at www.mdsinc.com or by calling
+1-888-MDS-7222, 24 hours a day.

ots Originaltext: MDS Nordion
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Shelley Maclean, External Communications Specialist, MDS Nordion,
Tel: +1-613-592-3400 ext. 2414, E-mail: shelley.maclean@mdsinc.com